See more : Drägerwerk AG & Co. KGaA (DGWPF) Income Statement Analysis – Financial Results
Complete financial analysis of Bellerophon Therapeutics, Inc. (BLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellerophon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Danske Bank A/S (DNSKF) Income Statement Analysis – Financial Results
- Indiabulls Housing Finance Limited (IBULHSGFIN.NS) Income Statement Analysis – Financial Results
- Shenzhen Lifotronic Technology Co., Ltd. (688389.SS) Income Statement Analysis – Financial Results
- Eternit S.A. (ETER3.SA) Income Statement Analysis – Financial Results
- ApartmentLove Inc. (APLV.CN) Income Statement Analysis – Financial Results
Bellerophon Therapeutics, Inc. (BLPH)
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -65.00K | -102.00K | -147.00K | -348.00K | -362.00K | -373.00K | -400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.36M | 13.02M | 17.89M | 11.03M | 20.26M | 17.85M | 16.65M | 33.37M | 45.98M | 52.99M | 38.73M |
| General & Administrative | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 0.00 | 9.01M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 13.78M | 9.01M | 7.19M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -674.00K | 27.88M | 24.60M | 23.76M | 48.24M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Cost & Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 378.00K | 184.00K | 95.00K | 109.00K | 79.00K | 0.00 | 0.00 |
| Interest Expense | 135.00K | 5.00K | 250.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 377.00K | 388.00K | 429.00K | 85.00K |
| EBITDA | -22.18M | -20.16M | -26.71M | -14.72M | -2.26M | -54.45M | -23.85M | -46.08M | -59.37M | -61.57M | -46.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.38M | -20.16M | -26.28M | -17.47M | -27.88M | -24.60M | -23.76M | -46.57M | -59.75M | -62.00M | -46.23M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 136.00K | 605.00K | -577.00K | 2.41M | 25.26M | -30.22M | -495.00K | 402.00K | 79.00K | 0.00 | 0.00 |
| Income Before Tax | -22.25M | -19.56M | -26.85M | -15.07M | -2.63M | -54.82M | -24.25M | -46.46M | -59.67M | -62.00M | -46.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.42M | -1.80M | -2.13M | -1.80M | -5.44M | 29.85M | -438.00K | 1.18M | 0.00 | 0.00 | 0.00 |
| Net Income | -19.83M | -17.76M | -24.73M | -13.27M | 2.81M | -54.82M | -23.81M | -46.46M | -59.67M | -62.00M | -46.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| EPS Diluted | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| Weighted Avg Shares Out | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
| Weighted Avg Shares Out (Dil) | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the...
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the...
Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present...
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in...
Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue...
Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Monitoring Committee (DMC) has...
Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present...
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results...
Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences
WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that data from its Phase 2 randomized, double-blind,...
Source: https://incomestatements.info
Category: Stock Reports